JP2020517600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517600A5 JP2020517600A5 JP2019556175A JP2019556175A JP2020517600A5 JP 2020517600 A5 JP2020517600 A5 JP 2020517600A5 JP 2019556175 A JP2019556175 A JP 2019556175A JP 2019556175 A JP2019556175 A JP 2019556175A JP 2020517600 A5 JP2020517600 A5 JP 2020517600A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- heterocycloalkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims 33
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 18
- 125000002947 alkylene group Chemical group 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 16
- 125000004404 heteroalkyl group Chemical group 0.000 claims 14
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 12
- 125000002993 cycloalkylene group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000000732 arylene group Chemical group 0.000 claims 6
- 125000004474 heteroalkylene group Chemical group 0.000 claims 6
- 125000005549 heteroarylene group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 101710113436 GTPase KRas Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 3
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 1
- 208000006286 Legius syndrome Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims 1
- 206010029748 Noonan syndrome Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010041329 Somatostatinoma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 102000053557 human K-Ras4B Human genes 0.000 claims 1
- 108700002490 human K-Ras4B Proteins 0.000 claims 1
- 102000049555 human KRAS Human genes 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 1
- 208000022982 optic pathway glioma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 0 CC(CC1)CC*1C(C)=O Chemical compound CC(CC1)CC*1C(C)=O 0.000 description 2
- CQASEQRRQRRTLY-UHFFFAOYSA-N C[n]1nc(C(NCc2c[n](CC3[U]C3)nn2)=O)c2c1cccc2 Chemical compound C[n]1nc(C(NCc2c[n](CC3[U]C3)nn2)=O)c2c1cccc2 CQASEQRRQRRTLY-UHFFFAOYSA-N 0.000 description 1
- NTEZNSBVTJXZID-SNVBAGLBSA-N Cc(cc1)ccc1S(c1c[n](C[C@H]2OC2)nn1)(=O)=O Chemical compound Cc(cc1)ccc1S(c1c[n](C[C@H]2OC2)nn1)(=O)=O NTEZNSBVTJXZID-SNVBAGLBSA-N 0.000 description 1
- CUNPROXJYKWQJP-NSHDSACASA-N O=C(c1c[nH]c2c1cccc2)NCc1c[n](C[C@@H]2OC2)nn1 Chemical compound O=C(c1c[nH]c2c1cccc2)NCc1c[n](C[C@@H]2OC2)nn1 CUNPROXJYKWQJP-NSHDSACASA-N 0.000 description 1
- CUNPROXJYKWQJP-LLVKDONJSA-N O=C(c1c[nH]c2ccccc12)NCc1c[n](C[C@H]2OC2)nn1 Chemical compound O=C(c1c[nH]c2ccccc12)NCc1c[n](C[C@H]2OC2)nn1 CUNPROXJYKWQJP-LLVKDONJSA-N 0.000 description 1
- FCQHSKPNEQRLKN-JTQLQIEISA-N O=C(c1n[nH]c2c1cccc2)NCc1c[n](C[C@@H]2OC2)nn1 Chemical compound O=C(c1n[nH]c2c1cccc2)NCc1c[n](C[C@@H]2OC2)nn1 FCQHSKPNEQRLKN-JTQLQIEISA-N 0.000 description 1
- FCQHSKPNEQRLKN-SNVBAGLBSA-N O=C(c1n[nH]c2c1cccc2)NCc1c[n](C[C@H]2OC2)nn1 Chemical compound O=C(c1n[nH]c2c1cccc2)NCc1c[n](C[C@H]2OC2)nn1 FCQHSKPNEQRLKN-SNVBAGLBSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487756P | 2017-04-20 | 2017-04-20 | |
| US62/487,756 | 2017-04-20 | ||
| PCT/US2018/028593 WO2018195439A2 (en) | 2017-04-20 | 2018-04-20 | K-ras modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517600A JP2020517600A (ja) | 2020-06-18 |
| JP2020517600A5 true JP2020517600A5 (https=) | 2021-06-10 |
Family
ID=62117061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556175A Pending JP2020517600A (ja) | 2017-04-20 | 2018-04-20 | Ｋ−Ｒａｓモジュレーター |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11358940B2 (https=) |
| EP (1) | EP3612526A2 (https=) |
| JP (1) | JP2020517600A (https=) |
| KR (1) | KR20200011426A (https=) |
| CN (1) | CN110785414A (https=) |
| AU (1) | AU2018255413A1 (https=) |
| BR (1) | BR112019021899A2 (https=) |
| CA (1) | CA3059943A1 (https=) |
| CL (1) | CL2019002968A1 (https=) |
| EA (1) | EA201992497A1 (https=) |
| EC (1) | ECSP19075354A (https=) |
| MA (1) | MA50014A (https=) |
| MX (1) | MX2019012532A (https=) |
| SG (1) | SG11201909570PA (https=) |
| TW (1) | TW201900638A (https=) |
| WO (1) | WO2018195439A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016258192B2 (en) | 2015-05-06 | 2021-07-29 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| KR102444509B1 (ko) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| US12440481B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| CN120097859A (zh) * | 2019-02-19 | 2025-06-06 | 加利福尼亚大学董事会 | Nurr1受体调节剂 |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| CN112574174B (zh) * | 2019-09-27 | 2021-12-07 | 恩瑞生物医药科技（上海）有限公司 | 蛋白降解靶向嵌合体类化合物及其制备方法和医药用途 |
| BR112022010924A2 (pt) | 2019-12-06 | 2022-09-06 | Vertex Pharma | Tetra-hidrofuranos substituídos como moduladores de canais de sódio |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| TW202210633A (zh) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
| TW202214574A (zh) * | 2020-06-08 | 2022-04-16 | 加拿大商愛彼特生物製藥公司 | 經取代之(呔-1-基甲基)脲類、經取代之n-(呔-1-基甲基)醯胺類及其類似物 |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| EP4263535A1 (en) | 2020-12-17 | 2023-10-25 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| US12378229B2 (en) | 2021-02-02 | 2025-08-05 | Liminal Biosciences Limited | GPR84 antagonists and uses thereof |
| WO2022221451A2 (en) * | 2021-04-13 | 2022-10-20 | University Of Virginia Patent Foundation | Sulfonyl-triazole compounds useful as ligands and inhibitors of prostaglandin reductase 2 |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| AR127064A1 (es) | 2021-09-15 | 2023-12-13 | Hua Medicine Shanghai Ltd | Prodroga de derivados de pirrolidona como activador de glucoquinasa |
| EP4416131A4 (en) * | 2021-10-15 | 2025-07-30 | Genetolead Inc | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF |
| TW202340202A (zh) * | 2021-12-22 | 2023-10-16 | 美國加利福尼亞大學董事會 | Gtp酶抑制劑及其用途 |
| CN115028678B (zh) * | 2022-07-08 | 2024-09-06 | 杭州医学院 | 基于vhl配体诱导bcr-abl蛋白降解的双功能分子及其制备方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3131527A1 (de) | 1981-08-08 | 1983-02-24 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| JPS61227567A (ja) | 1985-04-01 | 1986-10-09 | Eisai Co Ltd | １，４−ジヒドロピリジン誘導体 |
| DK626889A (da) | 1988-12-16 | 1990-06-17 | Roussel Uclaf | Indanderivater, deres fremstilling samt laegemidler med indhold deraf |
| IL111730A (en) | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same |
| WO1996006078A1 (en) | 1994-08-24 | 1996-02-29 | Pfizer Pharmaceuticals Inc. | N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists |
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| US5631251A (en) * | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | 5-cyclopropyl-1,4 benzodiazepine-2-ones |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| JP2003501414A (ja) | 1999-06-04 | 2003-01-14 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼの阻害剤 |
| WO2001012189A1 (en) * | 1999-08-12 | 2001-02-22 | Pharmacia Italia S.P.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| DE60033684T2 (de) * | 1999-11-18 | 2007-12-06 | Ajinomoto Co., Inc. | Phenylalaninderivate |
| WO2003004474A1 (en) * | 2001-07-06 | 2003-01-16 | Syngenta Participations Ag | Pesticidally active aminoacetonitriles |
| WO2004033427A1 (en) | 2002-10-11 | 2004-04-22 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| EP1636585B2 (en) * | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| US20050119266A1 (en) | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
| GB0326029D0 (en) | 2003-11-07 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| JPWO2005047286A1 (ja) | 2003-11-13 | 2007-05-31 | 小野薬品工業株式会社 | スピロ複素環化合物 |
| CA2551944A1 (en) * | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| DE602005016775D1 (de) | 2004-01-16 | 2009-11-05 | Wyeth Corp | Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion |
| ES2399447T3 (es) | 2006-02-17 | 2013-04-01 | F. Hoffmann-La Roche Ag | Derivados benzoil-piperidina como moduladores de 5HT2/D3 |
| CA2645652A1 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| KR20120003499A (ko) * | 2007-04-05 | 2012-01-10 | 지멘스 메디컬 솔루션즈 유에스에이, 인크. | 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조 |
| US20100267779A1 (en) | 2007-07-23 | 2010-10-21 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| CA2747354C (en) | 2008-12-19 | 2016-12-06 | Novartis Ag | Isoxazoline derivatives and their use as pesticide |
| MX373926B (es) * | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| AR082453A1 (es) | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| EP2698367A1 (en) | 2012-08-14 | 2014-02-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benzimidazoles for the treatment of cancer |
| WO2014093230A2 (en) | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| CA2904393A1 (en) | 2013-03-15 | 2014-09-25 | Araxes Pharma Llc | Covalent inhibitors of kras g12c |
| WO2015048570A2 (en) | 2013-09-26 | 2015-04-02 | Sanford-Burnham Medical Research Institute | Ebi2 modulators |
| EP3277678B1 (en) * | 2015-04-03 | 2020-03-18 | NantBio, Inc. | Compositions and methods of targeting mutant k-ras |
| AU2016258192B2 (en) | 2015-05-06 | 2021-07-29 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| PL3442947T3 (pl) * | 2016-04-15 | 2023-10-02 | Epizyme, Inc. | Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2 |
-
2018
- 2018-04-20 EP EP18723215.2A patent/EP3612526A2/en not_active Withdrawn
- 2018-04-20 KR KR1020197034310A patent/KR20200011426A/ko not_active Withdrawn
- 2018-04-20 MA MA050014A patent/MA50014A/fr unknown
- 2018-04-20 EA EA201992497A patent/EA201992497A1/ru unknown
- 2018-04-20 SG SG11201909570P patent/SG11201909570PA/en unknown
- 2018-04-20 CA CA3059943A patent/CA3059943A1/en active Pending
- 2018-04-20 TW TW107113553A patent/TW201900638A/zh unknown
- 2018-04-20 JP JP2019556175A patent/JP2020517600A/ja active Pending
- 2018-04-20 AU AU2018255413A patent/AU2018255413A1/en not_active Abandoned
- 2018-04-20 CN CN201880037317.9A patent/CN110785414A/zh active Pending
- 2018-04-20 MX MX2019012532A patent/MX2019012532A/es unknown
- 2018-04-20 US US16/605,643 patent/US11358940B2/en active Active
- 2018-04-20 WO PCT/US2018/028593 patent/WO2018195439A2/en not_active Ceased
- 2018-04-20 BR BR112019021899-8A patent/BR112019021899A2/pt not_active Application Discontinuation
-
2019
- 2019-10-17 CL CL2019002968A patent/CL2019002968A1/es unknown
- 2019-10-18 EC ECSENADI201975354A patent/ECSP19075354A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517600A5 (https=) | ||
| JP2014193925A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| CN103554042B (zh) | 调节hsp90活性的三唑化合物 | |
| JP2019527682A5 (https=) | ||
| JP2019507793A5 (https=) | ||
| PT1423115E (pt) | Actividade antiangiogénica de análogos da talidomida substituídos com nitrogénio | |
| JP2019500315A5 (https=) | ||
| JP2020534373A5 (https=) | ||
| JP2008523099A5 (https=) | ||
| JP2008508304A5 (https=) | ||
| JP2017519754A5 (https=) | ||
| WO1990005526A1 (fr) | Agent de traitement et de prophylaxie des troubles ischemiques du c×ur ou du cerveau | |
| JP2022511477A5 (https=) | ||
| JP2023518777A5 (https=) | ||
| JP2025517106A5 (https=) | ||
| JP2021510692A5 (https=) | ||
| JP2017524013A5 (https=) | ||
| JP2021505541A5 (https=) | ||
| JP2009526834A5 (https=) | ||
| JP2022520907A5 (https=) | ||
| US11219633B2 (en) | Nucleobase analogue derivatives and their applications | |
| JP2021527692A (ja) | Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法 | |
| JP2006521407A5 (https=) | ||
| JP2024517443A5 (https=) |